title: Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
abstract: BACKGROUND
  Much progress has been made in the last ten years in the treatment of non Hodgkin's lymphomas by increasing drug schedules and by using non cross-resistant regimens.
  
  
  METHODS
  So we decided in 1984 to test a new multiple drug protocol (Tours-Poitiers-Limoges = TPL protocol) which used a sequence of three courses of classical high-dose induction therapy, three courses of consolidation therapy using Teniposide, Cytosine Arabinoside, L Asparaginase and high-dose Methotrexate, and three courses of late intensification using the same drugs as induction therapy. Results. Thirty-eight patients younger than 60 years were included. Complete remission was obtained in 27 patients (71%). The median follow-up was 3 years and 9 months with one third of CR patients having been followed beyond 5 years. Seven patients relapsed (26% of CR patients) and one died of toxicity in complete remission. At present 22 patients (58%) are in complete remission, 19 in first CR, 1 in first CR after allogenic bone marrow transplantation, and 2 in second prolonged CR after autologous bone marrow transplantation. The median survival time is 48 months and the actuarial disease-free survival curve seems to have a plateau at 48.5%, with no relapse after 24 months.
  
  
  CONCLUSIONS
  These results confirm the efficacy of alternating high-dose conventional chemotherapy in the treatment of intermediate and high-grade NHL, with about half of the patients being cured. However, more intensive chemotherapy regimens are needed to improve cure rates.
authors.affiliation: Department of Haematology and Oncology, CHU Bretonneau, Tours, France.
authors.forename: P
authors.initials: P
authors.lastname: Colombat
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: D
authors.initials: D
authors.lastname: Bordesoule
authors.forename: P
authors.initials: P
authors.lastname: Renou
authors.forename: E
authors.initials: E
authors.lastname: Benz-Lemoine
authors.forename: L
authors.initials: L
authors.lastname: Fouillard
authors.forename: M
authors.initials: M
authors.lastname: Drouet
authors.forename: J
authors.initials: J
authors.lastname: Tanzer
authors.forename: J P
authors.initials: JP
authors.lastname: Lamagnere
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012074:Remission Induction; D018805:Sepsis / Q000209:etiology / Q000401:mortality; D015996:Survival Rate; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D011239:Prednisolone; D001215:Asparaginase; D014751:Vindesine; D008727:Methotrexate